Elad Tzahor, Ph.D. is a distinguished Full Professor at the Weizmann Institute of Science (WIS), where he has been a leading figure in the field of cardiac regeneration for over 20 years. With a Ph.D. from WIS and post-doctoral training at Harvard Medical School, Dr. Tzahor has established themselves as a thought leader in cardiac regenerative medicine, producing a seminal body of work that has significantly advanced the field. Throughout their illustrious career, Dr. Tzahor has been the recipient of numerous prestigious grants and awards, recognizing their groundbreaking research and contributions to cardiovascular science.

Kfir Umansky, Ph.D. is a seasoned scientist and former faculty member of the Weizmann Institute of Science (WIS). He is the former COO and founder of a translational oncology research center, bringing a wealth of experience in advancing cancer research. Dr. Umansky earned his Ph.D. from the Weizmann Institute of Science.

Mark Nuttall is the Chief Business Officer at Cambrian Bio. He was previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, and Kymera Therapeutics (KYMR). Before moving to biotech, Mark held increasingly senior roles in business development functions at several large pharmaceutical companies. He was Vice President and Head of Business Development & Licensing for core therapeutic franchises at Sanofi Genzyme: immunology, inflammation and multiple sclerosis; at Johnson & Johnson, he led neuroscience business development and was responsible for leading a team that transformed J&J’s CNS portfolio. Mark began his career in the healthcare industry in R&D at GlaxoSmithKline and AstraZeneca. He has a B.Sc. in biochemistry from the University College of Wales in Cardiff and a Ph.D. in molecular and cell biology from the University of Aberdeen, Scotland.

James Peyer is the Chief Executive Officer and Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

Erik Schneider is the VP of Strategy & Business Development at Cambrian Bio. Previously, Erik was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Erik was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Erik graduated from the College of the Holy Cross with a degree in Biochemistry.

Ruth Thieroff-Ekerdt, MD, serves as Chief Medical Officer at Cambrian Bio. Prior to joining Cambrian, she was Chief Medical Officer at Sojournix, and Acting CMO/Scientific Advisor at Organon. She also served as Chief Medical Officer at Aptalis, Strongbridge, Kaleido and held R&D positions of increasing responsibility at Bayer. She graduated as MD and Dr. med. from the Free University Berlin and specialized in Pharmacology and Clinical Pharmacology. She has over 30 years of experience in pharmaceutical R&D at all stages of discovery, development, and commercialization, with a successful track record of leading translational and development programs, submissions, and product launches in EU and US in various therapeutic areas and technologies. She also served as expert in the European Innovative Medicine Initiative and on the Scientific Advisory Board for Chr. Hansen. Ruth has published 28 scientific articles and conference contributions and is inventor/co-inventor of 31 patents.